Commit To Purchase Allergan At $97.50, Earn 5.2% Annualized Using Options

Investors considering a purchase of Allergan ( AGN) stock, but tentative about paying the going market price of $114.53/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the January 2015 put at the $97.50 strike, which has a bid at the time of this writing of $5.00. Collecting that bid as the premium represents a 5.1% return against the $97.50 commitment, or a 5.2% annualized rate of return (at Stock Options Channel we call this the YieldBoost).

START SLIDESHOW:
Top YieldBoost Puts of the S&P 500 »

Selling a put does not give an investor access to AGN's upside potential the way owning shares would, because the put seller only ends up owning shares in the scenario where the contract is exercised. And the person on the other side of the contract would only benefit from exercising at the $97.50 strike if doing so produced a better outcome than selling at the going market price. ( Do options carry counterparty risk? This and six other common options myths debunked). So unless Allergan, Inc sees its shares decline 15.1% and the contract is exercised (resulting in a cost basis of $92.50 per share before broker commissions, subtracting the $5.00 from $97.50), the only upside to the put seller is from collecting that premium for the 5.2% annualized rate of return.

Interestingly, that annualized 5.2% figure actually exceeds the 0.2% annualized dividend paid by Allergan, Inc by 5%, based on the current share price of $114.53. And yet, if an investor was to buy the stock at the going market price in order to collect the dividend, there is greater downside because the stock would have to lose 15.14% to reach the $97.50 strike price.

If you liked this article you might like

Stock Observations; Reviewing Equities: Doug Kass' Views

Allergan's Restasis Patent Transfer to Face Precedent-Setting Legal Battle

Teva's New CEO Brings This Secret Weapon

Will Allergan's Deal With Tribe Hold Up?

A Stampede of Buying: Cramer's 'Mad Money' Recap (Monday 9/11/17)